Rilematovir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

JNJ-678 is a novel inhibitor of the fusion protein. JNJ-678 shows the potential for respiratory syncytial virus (RSV) treatment.

JNJ-678 is a novel inhibitor of the fusion protein. JNJ-678 shows the potential for respiratory syncytial virus (RSV) treatment.(In Vitro):Rilematovir is highly active against a number of RSV strains from both A and B subtypes, especially the A2 strain. The EC50 of HeLa cells is 460?pM.(In Vivo):Rilematovir efficiently suppresses established acute lower respiratory tract infection in the animals after oral treatment of neonatal lambs with Rilematovir, or with an equally active close analog.

JNJ-678; JNJ-53718678

Others

Other Targets

——

——

——

1383450-81-4

500.9

C21H20ClF3N4O3S

>98% (HPLC)

——

CS(=O)(=O)CCCn1c(Cn2c3cnccc3n(CC(F)(F)F)c2=O)cc2cc(Cl)ccc12

——

(-20℃)

With Ice Pack

≥ 2 years